Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VXM-301
- Development stage
- Phase 1
- Lead developer
- Vaxxas
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
VXM-301 is a Vi-DT (Vi polysaccharide–diphtheria toxoid) typhoid conjugate vaccine being developed by Vaxxas, in collaboration with SK Bioscience, for the prevention of typhoid fever. The vaccine consists of the Vi polysaccharide capsular antigen of Salmonella enterica serovar Typhi (S. Typhi) conjugated to a diphtheria toxoid (DT) carrier protein. VXM-301 is uniquely formulated for needle-free transcutaneous delivery using Vaxxas's proprietary high-density microarray patch (HD-MAP) technology, which is designed to deliver the vaccine intradermally. This delivery system aims to provide a temperature-stable, low-cost vaccine option to improve access in low- and middle-income countries. VXM-301 is currently in Phase 1 clinical development evaluating its safety, tolerability, local skin reactogenicity, and exploratory immunogenicity in healthy adults.
- Other names
- Vi polysaccharide-diphtheria toxoid typhoid conjugate vaccineVi-DT typhoid conjugate vaccine
02
Targets
Vi antigen (Vi capsular polysaccharide)
Beyond the preview
Go deeper on VXM-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VXM-301.